3563-14-2

Basic information

• Product Name: sulfasuccinamide
• Synonyms: sulfasuccinamide;N4-SUCCINOYLSULFANILAMIDE;succinylsulfanilamide;4-[[4-(Aminosulfonyl)phenyl]amino]-4-oxobutyric acid;4-keto-4-(4-sulfamoylanilino)butyric acid;4-oxo-4-(4-sulfamoylanilino)butanoic acid;4-oxo-4-[(4-sulfamoylphenyl)amino]butanoic acid
• CAS NO: 3563-14-2
• Molecular Formula: C₁₀H₁₂N₂O₅S
• Molecular Weight: 272.28154
• EINECS: 222-632-8
• Mol File: 3563-14-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.52g/cm³
• Refractive Index: 1.622
• CAS DataBase Reference: sulfasuccinamide(CAS DataBase Reference)
• NIST Chemistry Reference: sulfasuccinamide(3563-14-2)
• EPA Substance Registry System: sulfasuccinamide(3563-14-2)

Safety Data

• Hazardous Substances Data: 3563-14-2(Hazardous Substances Data)

Usage

General Description

Sulfasuccinamide is a medication that belongs to a class of drugs known as sulfonamides, which work by stopping the growth of bacteria. It is used to treat a variety of bacterial infections, including urinary tract infections, bronchitis, and certain types of pneumonia. Sulfasuccinamide works by inhibiting the synthesis of folic acid, which is essential for the production of DNA and RNA in bacteria. This disrupts the bacteria's ability to multiply and survive, ultimately leading to their death. Common side effects of sulfasuccinamide include nausea, vomiting, diarrhea, and allergic reactions. It is important to use this medication as prescribed by a healthcare professional, as misuse or overuse can lead to the development of drug-resistant bacteria.

InChI:InChI=1/C10H12N2O5S/c11-18(16,17)8-3-1-7(2-4-8)12-9(13)5-6-10(14)15/h1-4H,5-6H2,(H,12,13)(H,14,15)(H2,11,16,17)

Upstream product

• 108-30-5 succinic acid anhydride 
• 63-74-1 sulfanilamide 
• 2158-14-7 4-acetamidobenzenesulfonyl azide 
• 14860-69-6 (p-aminobenzene)sulfonyl azide 
• 102-14-7 N-phenyl-succinamic acid 
• 40686-14-4 4-(2,5-dioxopyrrolidin-1-yl)benzenesulphonyl chloride 
• 83-25-0 N-phenylmaleimide 
• 858805-90-0 N-(4-sulfamoyl-phenyl)-succinamide 
• 161388-94-9 N-(p-sulfamoylphenyl)-3-carbomethoxypropionamide 
• 5694-39-3 N-(4-chlorosulfonyl-phenyl)-succinamic acid 
• 5470-06-4 N,N-succinyl-sulfanilic acid amide 

Downstream Products

• 5470-06-4 N,N-succinyl-sulfanilic acid amide 
• 1393723-68-6 (S)-methyl 3-(4-iodophenyl)-2-(4-oxo-4-(4-sulfamoylphenylamino)butanamido)propanoate 
• 1393723-78-8 (R)-2-(4-oxo-4-(4-sulfamoylphenylamino)butanamido)-3-(4'-(trifluoromethyl)biphenyl-4-yl)propanoic acid 
• 1393723-77-7 (R)-2-(4-oxo-4-(4-sulfamoylphenylamino)butanamido)-3-(3'-(trifluoromethyl)biphenyl-4-yl)propanoic acid 
• 1393723-76-6 (R)-3-(3',4'-dichlorobiphenyl-4-yl)-2-(4-oxo-4-(4-sulfamoylphenylamino)butanamido)propanoic acid 
• 1393723-75-5 (R)-3-(2',4'-difluorobiphenyl-4-yl)-2-(4-oxo-4-(4-sulfamoylphenylamino)butanamido)propanoic acid 
• 1393723-74-4 (R)-3-(biphenyl-4-yl)-2-(4-oxo-4-(4-sulfamoylphenylamino)butanamido)propanoic acid 
• 1393723-69-7 (R)-methyl 3-(4-iodophenyl)-2-(4-oxo-4-(4-sulfamoylphenylamino)butanamido)propanoate 
• 906812-33-7 3-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-N-(4-sulfamoylphenyl)propionamide 

Relevant articles and documents

PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors Can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas

A series of aromatic/heterocyclic bis-sulfonamides were synthesized from three established aminosulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor pharmacophores, coupled with either ethylene glycol oligomeric or polymeric diamines to yield bis-sulfonamides with short or long (polymeric) linkers. Testing of novel inhibitors and their precursors against a panel of membrane-bound CA isoforms, including tumor-overexpressed CA IX and XII and cytosolic isozymes, identified nanomolar-potent inhibitors against both classes and several compounds with medium isoform selectivity in a detailed structure-activity relationship study. The ability of CA inhibitors to kill tumor cells overexpressing CA IX and XII was tested under normoxic and hypoxic conditions, using 2D and 3D in vitro cellular models. The study identified a nanomolar potent PEGylated bis-sulfonamide CA inhibitor (25) able to significantly reduce the viability of colon HT-29, breast MDA-MB231, and ovarian SKOV-3 cancer cell lines, thus revealing the potential of polymer conjugates in CA inhibition and cancer treatment.

Synthesis, antiinflammatory, and antitumor activity of substituted succinamic acids

-

Facile synthesis, single crystal analysis, and computational studies of sulfanilamide derivatives

Antibacterial resistance is a worldwide problem. Sulfanilamide is widely used antibacterial. For the first time, we report here a simple method for the derivative synthesis of the title drugs, single crystal XRD and density functional theory (DFT) studies. The optimized molecular structure, natural bond orbital (NBO), frontier molecular orbitals (FMOs) molecular electrostatic potential studies (MEP) and Mulliken population analysis (MPA) have been performed using M06-2X/6-31G(d, p). The FT-IR spectra and thermodynamic parameters were calculated at M06-2X/6-311?+?G(2d,p) and B3LYP/6-31G(d, p) levels respectively, while, the UV–Vis analysis was performed using TD-DFT/B3LYP/6-31G(d, p) method. The experimental FT-IR spectra of both compounds were also carried out to reconfirm [sbnd]H?O[sbnd] hydrogen bonds. The DFT optimized parameters exhibiting good agreement with the experimental data. NBO analysis explored the hyper conjugative interaction and stability of title crystals, especially, reconfirmed the existence of [sbnd]H?O[sbnd] hydrogen bonds between the dimers. The FT-IR, thermodynamic parameters, MEP and MPA also revealed the hydrogen bonding detail is harmonious to XRD data. As a matter of the fact, the hydrogen bonding is a significant parameter for the understanding and design of molecular crystals, subsequently; it can also play a vital role in the supramolecular chemistry. Moreover, the global reactivity descriptors suggest that title compounds might be bioactive.